ArticleBMC cardiovascular disorders2025
Relation of glucose variability on mortality from any cause and cardiovascular diseases in individuals with type 2 diabetes: mediation analysis of echocardiographic parameters.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to explore the relationship between glucose variability (GV) and echocardiographic parameters and to investigate the mediating effect of echocardiographic parameters in the association of GV with all-cause and cardiovascular mortality.
methodsIn this retrospective cohort study, we acquired data from the electronic health records of individuals with type 2 diabetes mellitus (T2DM) who visited a medical center during 2001–2020 (Jan to Oct) with follow-up until December 31, 2021. Cox proportional hazards models were conducted to explore the relationship of GV and echocardiographic parameters and mortality. We employed mediation analysis to assess the role of echocardiographic parameters in linking GV to mortality.
resultsThere were 3,996 patients with T2DM. Both variability in HbA1c and fasting plasma glucose (FPG) were significantly linked with mortality. FPG variability was correlated with left ventricular mass index (LVMI), left ventricular mass (LVM), e’, and tricuspid regurgitation (TR) velocity according to multivariable regression analyses. At a mean follow-up of 5.2 years, FPG variability, LVM, LVMI, s’, and TR velocity were independently linked with all-cause and expanded cardiovascular disease (CVD) mortality. LVM, LVMI, s’, and TR velocity mediated 3.04%, 3.75%, 2.19%, and 2.71% of the association between FPG variability and mortality from any cause, respectively; and s’ and TR velocity mediated 4.33% and 2.72% of the effect of FPG variability on expanded CVD mortality, respectively. All the tested echocardiographic parameters were not significant mediators of the relationship of HbA1c-CV with mortality from any causes and expanded CVD.
conclusionsOur study found a weak mediating effect of the echocardiographic parameters of cardiac structure and function in the association between FPG variability and mortality, but not in the association between HbA1c variability and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.